Literature DB >> 8700881

Characterization of small nontranslated polyadenylylated RNAs in vaccinia virus-infected cells.

C Lu1, R Bablanian.   

Abstract

Host protein synthesis is selectively inhibited in vaccinia virus-infected cells. This inhibition has been associated with the production of a group of small, nontranslated, polyadenylylated RNAs (POLADS) produced during the early part of virus infection. The inhibitory function of POLADS is associated with the poly(A) tail of these small RNAs. To determine the origin of the 5'-ends of POLADS, reverse transcription was performed with POLADS isolated from VV-infected cells at 1 hr and 3.5 hr post infection. The cDNAs of these POLADS were cloned into plasmids (pBS or pBluescript II KS +/-), and their nucleotide composition was determined by DNA sequencing. The results of this investigation show the following: There is no specific gene encoding for POLADS. The 5' ends of POLADS may be derived from either viral or cellular RNAs. Any RNA sequence including tRNAs, small nuclear RNAs and 5'ends of mRNAs can become POLADS if they acquire a poly(A) tail at their 3' ends during infection. This nonspecific polyadenylylation found in vaccinia virus-infected cells is probably conducted by vaccinia virus poly(A)+ polymerase. No consensus sequence is found on the 5' ends of POLADS for polyadenylylation. The 5' ends of POLADS have no direct role in their inhibitory activity of protein synthesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8700881      PMCID: PMC39905          DOI: 10.1073/pnas.93.5.2037

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  Selective inhibition of protein synthesis by synthetic and vaccinia virus-core synthesized poly(riboadenylic acids).

Authors:  R Bablanian; S K Goswami; M Esteban; A K Banerjee
Journal:  Virology       Date:  1987-12       Impact factor: 3.616

2.  Identification of a vaccinia virus gene encoding a type I DNA topoisomerase.

Authors:  S Shuman; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

3.  Transcription of orthopoxvirus telomeres at late times during infection.

Authors:  B L Parsons; D J Pickup
Journal:  Virology       Date:  1990-03       Impact factor: 3.616

4.  In vitro RNA synthesis with SP6 RNA polymerase.

Authors:  P A Krieg; D A Melton
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

5.  Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes.

Authors:  S Karlin; S F Altschul
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

Review 6.  Splicing of messenger RNA precursors.

Authors:  R A Padgett; P J Grabowski; M M Konarska; S Seiler; P A Sharp
Journal:  Annu Rev Biochem       Date:  1986       Impact factor: 23.643

7.  DNA sequence analysis with a modified bacteriophage T7 DNA polymerase.

Authors:  S Tabor; C C Richardson
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

8.  Comparison of a conserved region in fowlpox virus and vaccinia virus genomes and the translocation of the fowlpox virus thymidine kinase gene.

Authors:  M M Binns; F M Tomley; J Campbell; M E Boursnell
Journal:  J Gen Virol       Date:  1988-06       Impact factor: 3.891

9.  Vaccinia virus poly(A) polymerase. Specificity for nucleotides and nucleotide analogs.

Authors:  S Shuman; B Moss
Journal:  J Biol Chem       Date:  1988-06-15       Impact factor: 5.157

10.  Poly(riboadenylic acid) preferentially inhibits in vitro translation of cellular mRNAs compared with vaccinia virus mRNAs: possible role in vaccinia virus cytopathology.

Authors:  R Bablanian; A K Banerjee
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

View more
  8 in total

Review 1.  Tinkering with translation: protein synthesis in virus-infected cells.

Authors:  Derek Walsh; Michael B Mathews; Ian Mohr
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-01-01       Impact factor: 10.005

2.  Non-coding RNAs and heme oxygenase-1 in vaccinia virus infection.

Authors:  Clement A Meseda; Kumar Srinivasan; Jasen Wise; Jennifer Catalano; Kenneth M Yamada; Subhash Dhawan
Journal:  Biochem Biophys Res Commun       Date:  2014-10-18       Impact factor: 3.575

3.  Role of viral factor E3L in modified vaccinia virus ankara infection of human HeLa Cells: regulation of the virus life cycle and identification of differentially expressed host genes.

Authors:  Holger Ludwig; Jörg Mages; Caroline Staib; Michael H Lehmann; Roland Lang; Gerd Sutter
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

4.  Translation initiation: a regulatory role for poly(A) tracts in front of the AUG codon in Saccharomyces cerevisiae.

Authors:  Xuhua Xia; Vivian MacKay; Xiaoquan Yao; Jianhua Wu; Fumihito Miura; Takashi Ito; David R Morris
Journal:  Genetics       Date:  2011-08-11       Impact factor: 4.562

5.  Expression of a non-coding RNA in ectromelia virus is required for normal plaque formation.

Authors:  David J Esteban; Chris Upton; Casey Bartow-McKenney; R Mark L Buller; Nanhai G Chen; Jill Schriewer; Elliot J Lefkowitz; Chunlin Wang
Journal:  Virus Genes       Date:  2014-02       Impact factor: 2.198

6.  A Poxvirus Decapping Enzyme Colocalizes with Mitochondria To Regulate RNA Metabolism and Translation and Promote Viral Replication.

Authors:  Shuai Cao; Joshua A Molina; Fernando Cantu; Candy Hernandez; Zhilong Yang
Journal:  mBio       Date:  2022-04-18       Impact factor: 7.786

Review 7.  Vaccinia Virus as a Master of Host Shutoff Induction: Targeting Processes of the Central Dogma and Beyond.

Authors:  Pragyesh Dhungel; Fernando M Cantu; Joshua A Molina; Zhilong Yang
Journal:  Pathogens       Date:  2020-05-21

8.  Poxvirus-encoded decapping enzymes promote selective translation of viral mRNAs.

Authors:  Fernando Cantu; Shuai Cao; Candy Hernandez; Pragyesh Dhungel; Joshua Spradlin; Zhilong Yang
Journal:  PLoS Pathog       Date:  2020-10-08       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.